In the development of millions of treatments that can change inflammatory bowel diseases, researchers at Tel Aviv University discovered how to directly provide drugs directly to the intestine while bypassing the intestine, which is a long -term challenge to drug development. Breakthrough involves clever manipulation of small fat particles, these fat particles will treat molecules through blood.
“Everything in injection in the blood is eventually in the liver. This is the way of our anatomical structure,” Professor Dan Peer, deputy principal and Shumunis School of Biomedicine’s School of Biomedicine at the University of Traviv University, explained. And cancer research. “This constitutes two challenges. First of all, the aim of drugs for specific cells, especially organs, may be toxic to the liver. Second, we do not want to take drugs” stuck “in the liver.”
The research team has changed the composition of lipid nanoparticles (the same technology used in the COVID-19 vaccine) to create a molecular transport form that naturally flows to intestinal tissue. By increasing the proportion of specific fat molecules called phospholipids from 10 % to 30 %, they can directly lead the therapy molecules to their targets.
“This is the whole technique,” Peer pointed out. “We adjusted the lipid ingredients and found that the drug was directly targeted at the intestine when 30 % of phospholipids. This is not a blind repeated test. At least we understand the mechanism and realize that the ratio is more similar to natural creatures. Membrane, intestinal cells are more suitable for absorption. “
Researchers prove the effectiveness of their methods by successfully providing anti -inflammatory protein to treat the disease and colonitis in animal models. This method not only transmits molecularly to the inflammatory intestine, but also transforms immune cells into factories that produce anti -inflammatory compounds.
This development not only represents a new drug. It can change the paradigm of drug -targeted specific organs. The team is now exploring how to make its technologies adapting to other organs (such as pancreas). Traditionally, traditional drug transmission methods are difficult to achieve.
These meanings are far beyond inflammatory intestinal diseases. By fine -tuning the composition of these lipid nanoparticles, researchers may be able to create accurate targeted treatment methods for extensive diseases that affect specific organs, so as to reduce side effects and improve the treatment effect.
The research published in advanced science and opened up new possibilities for the treatment of the development of the expected goals more effectively than ever before. As Professor Peer pointed out: “The direct conveying method of this mRNA drug is new, and the possibility of more accurate therapy is wider than ever before.”
This research was cooperated with Dr. Riccardo Rampado with post -doctoral researcher, and his laboratory has been developing development in the field of MRNA Therapeutics. Their discovery shows that sometimes the most important breakthroughs do not come from the development of new drugs, but to find a smarter way to convey existing drugs.
If you find this work useful, consider supporting our work through one -time or monthly donations. Your contribution allows us to continue to bring you the accuracy that you can trust, and to be deeply scientific and medical news. Independent reports take time, energy and resources, and your support makes us likely to continue to explore stories important to you. Together, we can ensure that important discovery and development attracts them the most.
